Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

This trial is testing a treatment combination called Pola-R2 (polatuzumab vedotin, rituximab, and lenalidomide) as a first-line therapy for elderly patients aged 70 and over with diffuse large B-cell lymphoma (DLBCL) who are considered too frail or unfit to tolerate standard intensive chemotherapy. **You may be eligible if...** - You are 70 years or older with newly diagnosed DLBCL confirmed by biopsy - You have not yet received any chemotherapy (steroids alone are not counted as treatment) - A geriatric assessment has determined that you are unfit or frail - Your organ function and bone marrow reserves are adequate **You may NOT be eligible if...** - You have another active cancer in addition to the lymphoma - You have active hepatitis B infection - You have active, serious infections or unstable conditions affecting your heart, liver, kidneys, or metabolism Talk to your doctor to see if this trial is right for you.